EXANE DERIVATIVES - CTI BIOPHARMA CORP ownership

CTI BIOPHARMA CORP's ticker is CTICXXXX and the CUSIP is 12648L106. A total of 80 filers reported holding CTI BIOPHARMA CORP in Q1 2016. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
EXANE DERIVATIVES ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q3 2016$010.0%0.00%
Q2 2016$0
-100.0%
10.0%0.00%
Q1 2016$1,0000.0%10.0%0.00%
Q4 2015$1,0000.0%10.0%0.00%
Q3 2015$1,000
-99.8%
1
-99.7%
0.00%
Q2 2015$596,000
+5.1%
3000.0%0.00%
Q1 2015$567,000
-19.0%
3000.0%0.00%
Q4 2014$700,0003000.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q1 2016
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 10,698,618$13,159,00015.42%
BVF INC/IL 43,795,613$53,869,0009.18%
DAFNA Capital Management LLC 3,195,381$3,930,0003.50%
Sio Capital Management, LLC 5,292,262$6,509,0002.88%
NEXTHERA CAPITAL LP 656,000$807,0001.14%
Lombard Odier Asset Management (USA) Corp 1,357,456$1,670,0000.16%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,236,832$2,751,0000.11%
Consonance Capital Management LP 510,000$635,0000.08%
Candriam S.C.A. 1,515,000$1,863,0000.05%
SABBY MANAGEMENT, LLC 575,669$708,0000.04%
View complete list of CTI BIOPHARMA CORP shareholders